After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m
Venture capital investment in biopharmaceutical companies slowed significantly from the first to the second quarter of 2022 but it remains to be seen if the third quarter will have a similar decline a